I can appreciate both sides of the argument...lower prices are nice from a consumer perspective, and high R&D spending also is good.
Of course, pharma can't very well fund R&D to the same level with lower revenues or their stock prices would decline and the stockholders would have a fit. That'd be terrible. Obviously if revenues were to drop, R&D would have to be cut so as to maintain profits and thus the stock price. That's obvious, right?
But in particular:
Why do you think many drugs which American consumers want to re-import cost less? They are manufactured to lesser standards of quality.
This is a Big Lie, in the propaganda vernacular.
If the proposal was to allow uncleared importation of drugs that currently are not cleared in USA, the "lower standards of quality" claim likely would be true.
That however is not the proposal. Instead it is to allow
RE importation of drugs that have been
EXPORTED from USA to other countries,
AND ARE FROM THE SAME MARKETER AND MAKER AS THE SAME DRUG SOLD IN USA, where for various reasons that drug is marketed in the other countries to which it is exported at much lower prices than are charged to USA consumers.
Prices that are enough lower that the drug can be bought in another country at wholesale pricing, or even at retail pricing, and transported back to USA, and
still be cheaper than the exact same product is here.